MIRA INFORM REPORT

 

 

Report Date :           

05.01.2012

 

IDENTIFICATION DETAILS

 

Name :

P.T. ANUGERAH MENTARI DISTRINDO

 

 

Registered Office :

Komplek Taman Surya 1 Block CC No. 3, Jalan Daan Mogot Kav. 100, Jakarta Barat, 11460

 

 

Country :

Indonesia

 

 

Date of Incorporation :

03.04.2009

 

 

Com. Reg. No.:

No. AHU-17976.AH.01.01.TH.2009

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Trading and Distribution of Pharmaceutical Raw Materials

 

 

No. of Employees :

15

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

US$ 142,100

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30th, 2011

 

Country Name

Previous Rating

                   (30.06.2011)                  

Current Rating

(30.09.2011)

Indonesia

b1

b1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Name of Company

 

P.T. ANUGERAH MENTARI DISTRINDO

 

 

company Address

 

Head Office

Komplek Taman Surya 1 Block CC No. 3

Jalan Daan Mogot Kav. 100

Jakarta Barat, 11460

Indonesia

Phones             - (62-21) 5698 1139, 568 1248

Fax                   - (62-21) 5695 2189

E-mail               - anugerahmd@gmail.com

Building Area     - 2 storey

Office Space      - 120 sq. meters

Region              - Commercial

Status               - Rent

 

 

Date of Incorporation

 

03 April 2009

 

 

Legal Form

 

P.T. (Perseroan Terbatas) or Limited Liability Company

 

 

Company Reg. No.

 

The Ministry of Law and Human Rights

No. AHU-17976.AH.01.01.TH.2009

Dated 4 May 2009

 

 

Company Status

 

Private National Company

Permit by the Government Department

 

The Department of Finance

NPWP No. 02.881.121.4-036.000

 

 

Related Company

 

None

 

 

CAPITAL AND OWNERSHIP

 

Capital Structure :

Authorized Capital                            : Rp. 600,000,000.-

Issued Capital                                  : Rp. 600,000,000.-

Paid up Capital                                : Rp. 600,000,000.-

 

Shareholders/Owners :

a. Ms. Arlini Novalinna Lujanto                             - Rp. 360,000,000.-

    Address : Jl. Tavip I/18, RT. 005 RW. 014

                    Kel. Tanah Sereal, Kec. Tambora

                    Jakarta Barat

                    Indonesia 

b. Mr. Teddy Gunawan                                          - Rp. 240,000,000.-

    Address : Jl. Kav. Polri Block A VII/181, RT. 005

                    RW. 009, Kel. Jelambar, Kec. Grogol

                    Petamburan, Jakarta Barat

                    Indonesia

 

 

BUSINESS ACTIVITIES

 

Lines of Business :

Trading and Distribution of Pharmaceutical Raw Materials

 

Production Capacity :

None

 

Total Investment :

None

 

Started Operation :

May 2009

 

Brand Name :

Anugerah Mentari Distrindo

 

Technical Assistance :

None

 

Number of Employee :

15 persons                                     

 

Marketing Area :

Local    - 100%

 

Main Customer :

Pharmaceutical Industry

 

Market Situation :

Very Competitive

 

Main Competitors :

a. P.T. BRATACO

b. P.T. CIPTA PRIMA CHEMINDO

c. P.T. GRAND KEMINDO PRATAMA

d. P.T. LAUTAN LUAS Tbk

e. Etc.

 

Business Trend :

Growing

 

 

BANKER, AUDITOR & LITIGATION

 

Banker :

P.T. Bank CENTRAL ASIA Tbk

Jalan Daan Mogot No. 95

Jakarta Barat

Indonesia

 

Auditor :

Internal Auditor

 

Litigation :

No litigation record in our database

 

 

FINANCIAL FIGURE

 

Annual Sales (estimated) :

2009 – Rp.   7.0 billion (May – December)

2010 – Rp.   9.0 billion

2011 – Rp. 10.8 billion

 

Net Profit (estimated) :

2009 – Rp. 350 million (May – December)

2010 – Rp. 495 million

2011 – Rp. 605 million

 

Payment Manner :

Average

 

Financial Comments :

Satisfactory

 

 

KEY EXECUTIVES

 

Board of Management :

Director                                           - Ms. Arlini Novalinna Lujanto

Marketing                                        - Mr. Mervin Sitohang

 

Board of Commissioners :

Commissioner                                 - Mr. Teddy Gunawan

 

Signatories :

Director (Ms. Arlini Novalinna Lujanto) which must be approved by Board of Commissioner

 

 

CAPABILITIES

 

Management Capability :

Satisfactory

 

Business Morality :

Satisfactory

 

Credit Risk :

Average

 

Credit Recommendation :

Credit should be proceeded with monitor

 

Proposed Credit Limit :

Small amount – periodical review

 

Maximum Credit Limit :

US$ 142,100 on 90 days D/A

 

OVERALL PERFORMANCE

 

P.T. ANUGERAH MENTARI DISTRINDO (P.T. AMD) was established in Tangerang, West Jakarta based on notary deed of Mr. Hadi Winata, SH., No. 02 dated 3 April 2009 with an authorized capital of Rp. 600,000,000 wholly issued and paid up. The founding and shareholders of the company are Ms. Arlini Novalinna Lujanto (60%) and Mr. Teddy Gunawan (40%) both are Indonesian businessmen of Chinese origins. Based on our knowledge up to writing the report the notary documents of the company have not undergone any changes. The company notary act was made by was approved by the Ministry of Law and Human Right in its Decision Letter No. AHU-17976.AH.01.01.TH.2009 dated May 4, 2009.

 

P.T. AMD is a private national company dealing with trading, import and distribution of pharmaceutical raw materials. P.T. AMD has been operating since May 2009 by sells and distribute of various type of chemical raw materials for pharmaceutical such as vitamin, herbal, gelatin (capsule), xantin, B2-simpatomimetika, parasimpatolitika, bromheksin, guaifenisin, karbosistein and others. Mr. Mervin Sitohang, marketing executive of the company disclosed the whole merchandise goods products imported in form of liquid, powder and crystal of Germany, China, and India.

 

Mr. Mervin Sitohang also added the company is a distributor for PHARMA WALDOF GmbH of Germany. The whole pharmaceutical raw materials marketed and supplied to various pharmaceutical industries among others are P.T. APEX PHARMA INDONESIA, P.T. SUNTHI SEPURI, P.T. YANTHI UTAMA, P.T. PRATAPA NIRMALA, P.T. BINTANG KUPU KUPU, P.T. ARTOIS FARMA, P.T. BIMA MITRA FARMA, P.T. CORSA INDUSTRIES, P.T. EAGLE INDO PHARMACEUTICAL and P.T. YARINDO FARMATAMA. We observe P.T. AMD is classified a small sized business of its kinds of which operation has been growing and developing well in the last three years.

 

Generally, demand for pharmaceutical raw materials, laboratory and medical equipment and various pharmaceutical products had been growing in the last five years up to the end 2010 as pictured in sales value of national pharmaceutical products, import value and export value issued by the Food and Drug Controlling Board (BPOM). The national pharmaceutical sales, export and import value of products are estimated to be rising by 6% to 8% in the next year. The competition is very tight on account many similar companies operating in the country. The business position of P.T. AMD is a sufficiently fairly good because the company has captive market in pharmaceutical industries in the country. According the BPOM that national pharmaceutical sales as shown are as the following table.

 

National Market Trend of Drugs, 2001-2010 (Billion Rupiah)

 

Year

Total Market

Ethical Drugs

Generic Drugs

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

12.850

15.483

17.458

20.872

23.629

23.173

25.600

29.981

33.965

37.531

  7.891

  9.618

10.829

12.706

14.675

13.834

13.959

16.969

19.225

21,142

1.547

1.694

1.819

2.136

2.529

2.390

2.295

3,213

3.420

3.610

          Source: Food and Drug Controlling Board (BPOM)

    

Until this time P.T. AMD has not been registered with Indonesian Stock Exchange, so that they shall not obliged to announce their financial statement. The management of P.T. AMD is very reclusive towards outsiders and rejected to disclose its financial condition. We observed that total sales turnover of the company in 2009 amounted to Rp. 7.0 billion rose to Rp. 9.0 billion in 2010 increased to Rp. 10.8 billion in 2011 and projected to go on rising by at least 6% in 2012. The operation in 2011 yielded an estimated net profit of at least Rp. 605 million and the company has an estimated total net worth of at least Rp. 1.0 billion. So far, we did not heard that the company having been black listed by the Central Bank (Bank Indonesia). The company usually pays its debts punctually to suppliers.  

 

The management of P.T. AMD is led by Ms. Arlini Novalinna Lujanto (51) a businesswoman and professional manager with experience in trading, import and distribution of pharmaceutical raw materials. The company's management is handled by professional staff in the above business. They have wide relations with private businessmen within and outside the country.

 

 

So far, we did not hear that the management of the company being filed to the district court for detrimental cases or involved in any business malpractices. The company’s litigation record is clean and it has not registered with the black list of Bank of Indonesia. P.T. ANUGERAH MENTARI DISTRINDO is sufficiently fairly good for business transaction.

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.53.14

UK Pound

1

Rs.83.08

Euro

1

Rs.69.25

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.